8-K: Quipt Forms Strategic JV, Expands Midwest Footprint

Quipt Home Medical Corp. announced a definitive agreement to acquire a 60% ownership interest in Hart Medical Equipment, forming a strategic joint venture with major health systems.

Summary

• Quipt Home Medical Corp. (QHMC) acquired a sixty percent (60%) membership interest in IRB Medical Equipment, LLC, dba Hart Medical Equipment (Hart).
• The remaining forty percent (40%) interest will be retained by the Seller (Hart HoldCo, LLC), which previously received 100% equity interests from Henry Ford Health, McLaren Health Management Group, and Northwest Ohio Medical Equipment, LLC.
• The acquisition is structured as a joint venture, with Quipt and the Seller jointly owning the Company.
• Hart Medical Equipment is a Michigan-based durable medical equipment provider with over 20 years of experience, operating 29 branch locations across Michigan and Ohio.
• Hart generated approximately $60 million in revenue and $7 million in Adjusted EBITDA for the twelve months ended June 2025.
• Quipt expects to consolidate Hart's financial results, projecting an annualized run-rate revenue of approximately $300 million post-closing.
• The purchase price for the 60% interest is 60% of an enterprise value of $35 million, subject to adjustments based on cash on hand (not less than $1,000,000), reduced by Company indebtedness, accrued payroll, certain Medicaid settlement amounts, and other non-trade payables, and adjusted for working capital surplus or deficit.
• The expected cash price for the acquisition is in the range of $17 million to $18 million, to be paid at closing through existing cash and additional cash from its existing credit facility, subject to lender approval.
• A $250,000 fee may be payable to Hart if Quipt fails to obtain financing and does not close by September 30, 2025.

Sentiment

Score: 8

Explanation: The acquisition is highly strategic, immediately accretive to revenue and EBITDA, and establishes strong health system partnerships in new key markets. While there's a financing condition, the overall tone and projected benefits are very positive for future growth and market positioning.

Positives

• Strategic entry into Michigan and expansion in northern Ohio, strengthening the existing Midwest footprint.
• Adds approximately $60 million in revenue and $7 million in Adjusted EBITDA (LTM June 2025) from Hart.
• Increases Quipt's expected annualized run-rate revenue to approximately $300 million post-closing.
• Establishes deep, longstanding strategic relationships with major health systems including Henry Ford Health, McLaren Health Care, Blanchard Valley Health System, Wood County Hospital, and The Bellevue Hospital.
• Embeds Quipt into the hospital discharge processes of more than 19 hospitals and affiliated care facilities.
• Provides direct access to a large, consistent patient base, serving over 67,000 patients monthly.
• Strengthens Quipt's strategy of expanding health system relationships and building scalable integration models.
• Positions Quipt favorably in the evolving value-based care reimbursement environment.
• Management anticipates Adjusted EBITDA margin to align with historical corporate averages within three quarters post-closing.
• Expected synergies through operational efficiencies and cross-market integration.
• The joint venture model is seen as a repeatable template for future growth nationwide.

Negatives

• The acquisition is subject to approval by the lender to Quipt's existing credit facility.
• Quipt may incur a $250,000 fee if financing is not obtained and the transaction does not close by September 30, 2025.
• The financial information regarding Hart disclosed in the press release is unaudited and derived from Quipt's due diligence, including a review of Hart's bank statements and tax returns.

Risks

• Risks related to credit, market (including equity, commodity, foreign exchange and interest rate), liquidity, operational (including technology and infrastructure), reputational, insurance, strategic, regulatory, legal, environmental, and capital adequacy.
• General business and economic conditions in the regions in which the Company operates.
• Ability to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans, and to attract, develop and retain key executives.
• Difficulty integrating newly acquired businesses.
• Ability to implement business strategies and pursue business opportunities.
• Low profit market segments.
• Disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services.
• Evolution of various types of fraud or other criminal behavior to which the Company is exposed.
• Failure of third parties to comply with their obligations to the Company or its affiliates.
• Impact of new and changes to, or application of, current laws and regulations.
• Decline of reimbursement rates.
• Dependence on few payors.
• Possible new drug discoveries.
• Novel business model.
• Dependence on key suppliers.
• Granting of permits and licenses in a highly regulated business.
• Legal proceedings and litigation, including as it relates to the civil investigative demand (CID) received from the Department of Justice.
• Increased competition.
• Changes in foreign currency rates.
• Imposition of trade restrictions such as tariffs and retaliatory countermeasures.
• Increased funding costs and market volatility due to market illiquidity and competition for funding.
• Availability of funds and resources to pursue operations.
• Critical accounting estimates and changes to accounting standards, policies, and methods used by the Company.
• The Company's status as an emerging growth company and a smaller reporting company.
• Occurrence of natural and unnatural catastrophic events or health epidemics or concerns.
• The Company not being impacted by any further external and unique events like the Medicare 75/25 rate cut and the Change Healthcare cybersecurity incident for the remainder of 2025.
• The Company not being subject to a material change to its cost structure.

Future Outlook

Quipt expects to consolidate Hart's financial results, leading to an annualized run-rate revenue of approximately $300 million. Management anticipates Adjusted EBITDA margin for the joint venture to align with historical corporate averages within three quarters post-closing, with synergies from operational efficiencies and cross-market integration. The company also expects a return to historical organic growth levels in calendar 2025 and views this joint venture as a repeatable model for future expansions.

Management Comments

• "The Hart Medical board was very focused on finding the right strategic partner to align with our mission of not only caring for patients at home following their discharge but also supporting their ongoing transitional care needs." Barton P. Buxton, Ed.D., Board Chair, Hart Medical.
• "Of all the potential partners, Quipt Home Medical demonstrated the strongest platform and shared commitment to continue and expand the important work Hart Medical has begun." Barton P. Buxton, Ed.D., Board Chair, Hart Medical.
• "Harts impressive footprint across Michigan and Ohio and its relationship with world-class health systems like Henry Ford Health, McLaren Health, and Blanchard Valley, bring a new level of depth and reach to our platform." Greg Crawford, CEO and Chairman of Quipt.
• "This transaction expands our service network to more than 19 hospitals and affiliated care facilities, dramatically increasing our ability to serve patients at critical points of care transition." Greg Crawford, CEO and Chairman of Quipt.
• "This joint venture marks a significant step forward in expanding our platform in a disciplined and strategic manner." Hardik Mehta, Chief Financial Officer.
• "We anticipate funding this transaction using cash on hand and our existing credit facility." Hardik Mehta, Chief Financial Officer.
• "As we integrate operations, we see clear opportunities to align operating systems and share best practices that will enhance operational efficiency, support sustainable growth and optimize financial performance." Hardik Mehta, Chief Financial Officer.
• "This is exactly the type of health system-aligned expansion we have been targeting, and we are confident that the Hart joint venture will serve as a repeatable model for future joint ventures, as we continue to build a diversified, national platform capable of delivering strong patient outcomes and long-term shareholder value." Hardik Mehta, Chief Financial Officer.

Industry Context

The acquisition aligns with the broader healthcare trend of integrating durable medical equipment (DME) providers more closely with health systems to manage patient care post-discharge and within value-based care models. This move positions Quipt to capitalize on the shift towards managing critically ill populations at home and supports the evolving reimbursement environment that increasingly drives risk management. The focus on deep health system partnerships and embedding into hospital discharge processes reflects a strategic response to industry demands for coordinated, efficient patient transitions.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or external benchmarks for direct comparison of results. However, management expects the joint venture's Adjusted EBITDA margin to align with Quipt's historical corporate averages within three quarters post-closing.

Stakeholder Impact

• Shareholders: Potential for increased long-term shareholder value through expanded revenue, EBITDA, market presence, and strategic partnerships.
• Patients: Enhanced transitional care services and improved patient outcomes through an expanded service network and integration into hospital discharge processes.
• Employees (Hart Medical): Integration into a larger platform (Quipt) with potential for operational efficiencies and shared best practices.
• Health Systems (Henry Ford Health, McLaren Health Care, etc.): Strengthened collaboration for managing critically ill populations and supporting ongoing transitional care needs.

Next Steps

• Closing of the transaction by the end of Fiscal Q4, 2025, subject to customary closing conditions, including lender approval.
• Integration of Hart's operations, aligning operating systems and sharing best practices.
• Achieving Adjusted EBITDA margin alignment with historical corporate averages within three quarters post-closing.
• Return to historical organic growth levels in calendar 2025.
• Utilizing the joint venture as a repeatable model for future expansions.

Key Dates

Recommendation

The acquisition of a 60% interest in Hart Medical Equipment is a highly strategic and financially accretive move for Quipt. It immediately adds $60 million in revenue and $7 million in Adjusted EBITDA, boosting Quipt's annualized run-rate revenue to $300 million. The transaction provides direct entry into the key Michigan market and strengthens its Midwest footprint, while establishing deep, long-term partnerships with major health systems. This integration into hospital discharge processes and alignment with value-based care trends positions Quipt for sustainable organic growth and operational efficiencies. The expected alignment of EBITDA margins and the repeatable joint venture model suggest strong future performance and significant long-term shareholder value creation, despite the minor financing contingency.

Keywords

Durable Medical Equipment, DME, Home Medical Equipment, HME, Respiratory Care, Joint Venture, Acquisition, Healthcare, Michigan, Ohio, Henry Ford Health, McLaren Health Care, Blanchard Valley Health System, Value-Based Care, Post-Acute Care, QIPT